SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

CNJ-016

EBS·Emergent BioSolutions Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market. CNJ-016 received initial FDA approval in 2005 and has been commercially available for nearly two decades.
Why 4/10
CNJ-016 is already FDA-approved and commercially marketed (since 2005) with no pending regulatory decision or pivotal readout in the next 12 months. Its revenue comes from periodic U.S. government contract awards under an existing 10-year framework, not from a binary catalyst. Therefore the impact score is capped at 4.
Actionable Insight NEUTRAL

CNJ-016 is already approved and generating revenue through government stockpile contracts. Watch for future ASPR contract option exercises under the existing 10-year agreement and any changes in U.S. biodefense spending priorities, which directly drive the drug's revenue stream. The next catalyst is not a binary regulatory event but continued contract awards, making this a slow-burn commercial story rather than a binary biotech bet.

Price Chart

Loading chart...

Executive Summary

CNJ-016 (Vaccinia Immune Globulin Intravenous, VIGIV) is an FDA-approved plasma-derived antibody therapy for treating complications from smallpox vaccination. First approved in 2005, it is manufactured by Emergent BioSolutions (NYSE: EBS) and sold almost exclusively to the U.S. government for the Strategic National Stockpile under a 10-year contract valued at approximately $535 million. The drug is a mature, approved product with no pending regulatory binary; its revenue depends on periodic government contract options being exercised. In 2026, the company secured $54 million in new U.S. orders and additional international business. However, Q3 2026 results showed smallpox medical countermeasure revenues (including CNJ-016) fell 68% year-over-year, contributing to a 52% total revenue decline and a post-earnings stock drop of roughly 18.6%.

How It Works

CNJ-016 (VIGIV) is a sterile solution containing high levels of antibodies (immune globulins) derived from the blood plasma of healthy donors who were previously vaccinated against smallpox. When infused into a patient, these antibodies provide passive immunity by neutralizing the vaccinia virus, helping the body fight off serious complications that can arise from the smallpox vaccine itself, such as severe skin infections or progressive viral illness.

Trial Status

CNJ-016 is FDA-approved (BLA 125109, 2005) and commercially marketed. A Phase 4 post-marketing study (NCT01374984) is ongoing to verify clinical benefits in patients with smallpox vaccination complications. An Expanded Access IND protocol also exists for treatment of orthopoxvirus infections.

The Two-Sided Case

▲ Bull Case5
CNJ-016 is the only FDA-licensed polyclonal antibody therapeutic for complications from smallpox vaccination, giving it a unique, competition-free position in the U.S. Strategic National Stockpile.
A 10-year contract (2019) valued at ~$535M provides a long-term revenue backbone. In 2026 alone, ASPR exercised a $54M option (March) and a $51.9M contract modification (July 2025) was awarded, demonstrating sustained government demand.
Analyst consensus is bullish: 5 Buy/Strong Buy ratings vs 1 Hold and 1 Sell, with a mean price target of $11 (implied ~61.5% upside from the $6.81 close on Nov 2, 2026).
Institutional accumulation was strong in Q2 2026: Millennium Management doubled its position, Goldman Sachs added, and Federated Hermes added, among others.
The drug could see expanded use under an Expanded Access IND protocol for treatment of orthopoxvirus infections (including mpox), broadening its addressable market beyond smallpox vaccination complications.
▼ Bear Case5
Revenue concentration risk: The U.S. Government (HHS/ASPR) is the principal customer for CNJ-016, making the drug dependent on government biodefense budgets and political priorities.
Q3 2026 saw smallpox MCM revenues (including CNJ-016) drop 68% year-over-year, with lower USG and international sales of CNJ-016 cited as a factor. The company's total Q3 revenue fell 52% to $110M, and adjusted EBITDA swung to a $4.6M loss.
The stock fell ~18.6% in post-market trading on November 2, 2026, after Q3 earnings missed revenue estimates ($110M vs $123.22M consensus) and the company cut its 2026 outlook.
Insider sales in October 2026: a director sold $126K worth of shares and an SVP sold $19.6K, both under 10b5-1 plans.
As a plasma-derived biologic, CNJ-016 faces manufacturing complexity and supply-chain risks inherent to blood products.

Upcoming Catalysts

  • Future U.S. government contract option exercises under the existing 10-year ASPR agreement (75A50119C00037)
  • Potential expanded use under the orthopoxvirus Expanded Access IND protocol
  • Any changes in U.S. biodefense funding or smallpox preparedness policy

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Emergent BioSolutions Inc. 8-K EBS ·Originating report

Sources · 11

Hover a chip for the title
1 investors.emergentbiosolutions.com2 investors.emergentbiosolutions.com3 nasdaq.com4 tradingkey.com5 marketbeat.com6 drugs.com7 fda.gov8 dailymed.nlm.nih.gov9 globalbiodefense.com10 stocklight.com11 assyro.com